zoledronic acid has been researched along with Hematologic Malignancies in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Chae, YS; Kim, JG; Kim, SN; Kim, YJ; Lee, SJ; Moon, JH; Sohn, SK | 1 |
| Lortholary, A | 1 |
1 review(s) available for zoledronic acid and Hematologic Malignancies
| Article | Year |
|---|---|
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematologic Neoplasms; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Prognosis; Recurrence; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2001 |
1 trial(s) available for zoledronic acid and Hematologic Malignancies
| Article | Year |
|---|---|
Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Pilot Projects; Stem Cell Transplantation; Steroids; Transplantation, Homologous; Zoledronic Acid | 2009 |
1 other study(ies) available for zoledronic acid and Hematologic Malignancies
| Article | Year |
|---|---|
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |